Beside the lens of biopharmaceutical contract research organization (CRO) PAREXEL, this case follows the evolution of the business as it re-identifies itself in response to the transformation of the CRO sector from a small, secondary bunch of businesses into a major player with crucial capabilities for worldwide drug development. While many of its opponents focus on cost cutting as PAREXEL is pursuing an exclusive globalization and IT strategy, the case commences.
Over the past 20 years, CEO Josef von Rickenbach had grown PAREXEL into a billion-dollar business by making bold investments predicated on customer demand and anticipated industry trends and taking calculated risks. Now, despite slowing demand for CRO services, PAREXEL is betting that a world-wide footprint and technology capabilities will become its key competitive advantage that is prospective. Close to the end of the case, the time transitions to a decade after Rickenbach made this strategic choice, describing PAREXEL's place within it and the development of the business.
PUBLICATION DATE: September 26, 2013 PRODUCT #: 314056-PDF-ENG
PAREXEL International Corp Stages of Innovation Case Study Solution
This is just an excerpt. This case is about LEADERSHIP & MANAGING PEOPLE
Related Case Solutions & Analyses:
British Columbia Ferry Services Inc.: Charting a Safe Course
Changing Contexts for Reputation Management
Contribution of Art/Design to Social and Political movement
Vista-Sci Health Care Inc.
Marshall & Gordon: Designing an Effective Compensation System (A)
Shell Nigeria: The WikiLeaks Cables, Chinese Version
Vlaad and Company: Recruiting Women in the Capital Markets
Arck Systems (E)
On Writing Teaching Notes Well
Sarbanes-Oxley Act
